Drugline is a fortnightly electronic drug bulletin providing information on new medicines, new developments, current affairs, new indications, new PBS listings and deletions and general issues of importance to all health professionals. Click below to view the most recent volumes of Drugline.
The product information for Cardizem® (diltiazem) has recently been updated to include the potential for an interaction with direct-acting oral anticoagulants (DOACs). Diltiazem is a moderate inhibitor of cytochrome P450 3A4 and a weak…
Read more
Icosapent ethyl is now listed on the Pharmaceutical Benefits Scheme (PBS) for patients with established atherosclerotic cardiovascular disease with hypertriglyceridaemia. To be eligible for PBS-subsidy, treatment must be in conjunction with lifestyle modification and…
Read more
The Pharmaceutical Benefits Scheme (PBS) listing for cabozantinib has been expanded to include non-clear cell renal cell carcinoma (RCC). Cabozantinib is now PBS subsidised for stage IV RCC (clear cell and non-clear cell) in…
Read more
The Pharmaceutical Benefits Scheme (PBS) listing for trastuzumab deruxtecan has recently been expanded to include human epidermal growth factor receptor 2 (HER2)-low unresectable or metastatic breast cancer. Breast cancer patients have historically been classified…
Read more
The Therapeutic Goods Administration (TGA) has issued a safety update for azithromycin. New warnings have been added to the azithromycin product information and consumer medicine information documents regarding a transient increased risk of cardiovascular…
Read more
An oromucosal formulation of midazolam is now available on the Pharmaceutical Benefits Scheme (PBS) for the treatment of generalised convulsive status epilepticus. Zyamis® pre-filled syringes are ready to use and are presented in four…
Read more
